[{"address1": "830 Winter Street", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "857 399 9500", "website": "https://www.tscan.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors. In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 145, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gavin  MacBeath Ph.D.", "age": 53, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 650173, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stephen J. Elledge Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tomasz  Kula Ph.D.", "title": "Co-Founder & Member of Advisory Board", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jason A. Amello", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Leiden  Dworak M.B.A.", "title": "Principal Accounting Officer & Treasurer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Justin  McCue Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zoran  Zdraveski J.D., Ph.D.", "age": 52, "title": "Chief Legal & Strategy Officer and Company Secretary", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ann  Hargraves", "title": "Senior Vice President of Human Resources", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shrikanta  Chattopadhyay M.D.", "title": "Senior VP & Head of Translational Medicine", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Debora  Barton M.D.", "age": 47, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 7.03, "open": 6.8, "dayLow": 6.8, "dayHigh": 7.35, "regularMarketPreviousClose": 7.03, "regularMarketOpen": 6.8, "regularMarketDayLow": 6.8, "regularMarketDayHigh": 7.35, "beta": 0.862, "forwardPE": -5.8666663, "volume": 115305, "regularMarketVolume": 115305, "averageVolume": 162453, "averageVolume10days": 155850, "averageDailyVolume10Day": 155850, "bid": 7.11, "ask": 7.21, "bidSize": 800, "askSize": 1400, "marketCap": 336685888, "fiftyTwoWeekLow": 1.62, "fiftyTwoWeekHigh": 7.87, "priceToSalesTrailing12Months": 19.883417, "fiftyDayAverage": 5.9094, "twoHundredDayAverage": 3.893025, "currency": "USD", "enterpriseValue": 207767504, "floatShares": 21012251, "sharesOutstanding": 43548100, "sharesShort": 252940, "sharesShortPriorMonth": 260257, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0053, "heldPercentInsiders": 0.008880001, "heldPercentInstitutions": 0.83235, "shortRatio": 2.61, "shortPercentOfFloat": 0.0066000004, "impliedSharesOutstanding": 5143130, "bookValue": 3.533, "priceToBook": 1.9926409, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -88328000, "trailingEps": -2.02, "forwardEps": -1.2, "enterpriseToRevenue": 12.27, "enterpriseToEbitda": -2.439, "52WeekChange": 1.1174698, "SandP52WeekChange": 0.27220368, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "TCRX", "underlyingSymbol": "TCRX", "shortName": "TScan Therapeutics, Inc.", "longName": "TScan Therapeutics, Inc.", "firstTradeDateEpochUtc": 1626442200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "78cfed2a-5d5f-3a28-9bf2-d5f7bc0c36ba", "messageBoardId": "finmb_583057578", "gmtOffSetMilliseconds": -18000000, "currentPrice": 7.04, "targetHighPrice": 15.0, "targetLowPrice": 7.0, "targetMeanPrice": 10.8, "targetMedianPrice": 9.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 215423008, "totalCashPerShare": 4.504, "ebitda": -85185000, "totalDebt": 86983000, "quickRatio": 6.498, "currentRatio": 6.563, "totalRevenue": 16933000, "debtToEquity": 51.481, "revenuePerShare": 0.354, "returnOnAssets": -0.24831, "returnOnEquity": -0.6185, "freeCashflow": -38036000, "operatingCashflow": -53602000, "revenueGrowth": 0.156, "operatingMargins": -6.36686, "financialCurrency": "USD", "trailingPegRatio": null}]